Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TINAG antisense RNA 1 (TINAG-AS1) is a long non-coding RNA (lncRNA) classified as an antisense transcript because it is transcribed from the DNA strand opposite to a protein-coding gene, specifically overlapping or corresponding to the TINAG gene[1]. Antisense RNAs, especially in the long non-coding class, are recognized as regulators of gene expression, often through interaction with the transcript (mRNA) of their associated sense gene, thereby influencing its processing, stability, splicing, or translation[4][6][7]. The specific function of TINAG-AS1 has not been extensively characterized in published literature or major gene databases as of now, and there are no known disease associations, therapeutic roles, or drug interactions[1]. Like other long non-coding antisense RNAs, TINAG-AS1 may play a role in the regulation of its sense gene (TINAG) or participate in broader gene regulation mechanisms, but this has not been experimentally established for TINAG-AS1 in particular.
Not applicable; TINAG-AS1 itself is not a drug target or direct effector molecule
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TINAG antisense RNA 1 (TINAG-AS1).